Vepalimomab

Drug Profile

Vepalimomab

Alternative Names: Anti-VAP-1 mouse monoclonal antibody; Anti-VAP-I mouse monoclonal antibody; Vapantix

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator BioTie Therapies
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dermatitis; Inflammatory bowel diseases; Psoriasis

Most Recent Events

  • 06 Nov 2002 BioTie Therapies and Carbion have merged with Contral Pharma
  • 08 Sep 2002 Discontinued - Clinical-Phase-Unknown for Inflammatory bowel disease in Finland (unspecified route)
  • 08 Sep 2002 Discontinued - Phase-I/II for Dermatitis in Finland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top